In December 2023, the joint HMA-EMA Big Data Steering Group (BDSG) published a multi-annual (2023-2028) AI workplan to guide use of AI in medicines development. The HMA and EMA recognize that pharmaceutical companies are increasingly using AI-powered tools in research, development and monitoring medicines. In this workplan it is stated that the aim is to embrace the opportunities of AI for personal productivity, automating processes and systems, increasing insights into data and supporting more robust...
January 16, 2024
4 min read
